Emmaus Life Sciences Announces Closing of $7.5 Million Private Placement

September 16, 2013

TORRANCE, Calif., September 16, 2013 – Emmaus Life Sciences, Inc. (the “Company,” or “Emmaus”), a biotherapeutics company dedicated primarily to the discovery, development and commercialization of innovative and cost effective treatments and therapies for debilitating rare diseases, today announced it has raised approximately $7.5 million in gross proceeds from a private placement to accredited investors, including two institutional investors.